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Abstracts / Urological Science 27 (2016) S36eS52 S51Materials and Methods: We recorded I-PSS, IIEF, European Organization
for Research and Treatment of Cancer Quality of Life Questionnaire-Core
30-item questionnaire (EORTC-QLQ-C30), catheterizations, and measure
urinary ﬂow and residual urine to evaluate the functional outcomes and in
the baseline, post-operation 1 and 2 years among the patient with bladder
cancer which received PRC and CRC.
Results: During 2007 to 2013, we identiﬁed 23 males with bladder cancer
who underwent neobladder reconstruction, 13 patients with PRC and the
other 10 patients with CRC. We found that there were better sexuality
preservation, continence rate and better global health status, functional
scales, and symptom scales in the PRC group.
Conclusion: For patients with bladder cancer underwent neobladder
reconstruction, prostate-sparing cystectomy provides better sexuality
preservation, continence rate, and quality of life.
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Purpose: Renal angiomyolipomas (AML) are benign tumors composed of
blood vessels, smooth muscle cells and fat cells. AML-related chronic
kidney disease and tumor bleeding are the main cause of mortality. AML
are highly associatedwith Tuberous Sclerosis Complex (TSC) andmostly be
treated by mammalian target of rapamycin inhibitor (mTORi) therapy or
transarterial embolization (TAE).
Materials and Methods: Here we present our cases of TSC-associated
renal AMLs treated with monotherapy or combined treatment of mTORi
and TAE. A total of 19 patients (4 males and 15 females) were included.
There were 10 patients treated by mTORi only and 9 by combined therapy
with mTORi and TAE.
Results: Themean age of the patientswas 34.5 (14e72) years. Themaximal
diameters of renal AMLs were from 1.5 to 20.9 (9.3±6.1) cm. During a mean
follow-up duration of 43 (6e81) months, the size of AMLs decreased
15e33% in 8 patients receiving combination therapy. Two patients under-
gone monotherapy experienced 30-50% increase of tumor diameter. The
tumor size of other patients showed no statistically signiﬁcant change.
Conclusion: TSC-associated AMLs are quite common in this hereditary,
complex syndrome. They are usually multiple and bilateral. The lesion
usually progress over time and complicated with ﬂank pain, hemorrhage,
and even renal deterioration. TSC-associated AMLs can be treated by
medication or minimally invasive therapy. Our result discovered although
the tumor size may not shrink, TAE still play an important role in man-
agement of tumor bleeding with acceptable complications. In our study,
combination therapy showed better control of tumor size than mono-
therapy alone in TSC-associated AMLs.
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Purpose: Early detection of prostate guideline from American Urological
Association (AUA) in 2013 does not recommend routine prostatic speciﬁc
antigen (PSA) screening in men younger than 55 year-old at average risk.
The purpose of this study is to investigate the characteristics of TRUS bi-
opsy for patients younger than age of 55, in a hope to assess the beneﬁt of
TRUS biopsy and the occurrence of prostate cancer in this population.Materials andMethods: Based on retrospective medical records, 812male
patients who received TRUS biopsy during December 2007 to December
2014 at Zhongxiao Branch of Taipei City Hospital were included. Of them,
57 men (7%) were younger than ﬁfty ﬁve year-old. We compare the age,
pre-biopsy, PSA, prostate size, and adenoma size between prostate cancer
group and benign prostatic hyperplasia group.
Results: In these 57 men, 6 of them (10.5%) had prostate cancer (group A),
and 51 men had benign prostatic hyperplasia (group B). The average age of
the group A and B was 51.0 ± 3.7 and 50.8 ± 3.1 year-old (P¼0.23). The
mean PSA of group A and B was 15.3 ± 12.3 and 7.2 ± 4.5 ng/ml (P<0.05).
The mean prostate size of group A and B was 23.3 ± 6.1 and 33.6 ± 14.8 ml
(P¼0.04). The mean adenoma size of group A and B was 8.7 ± 3.0 and
10.3 ± 5.5 ml (P¼0.12).
Conclusion: Among selected male patients younger than age of 55, TRUS
biopsy was with a positive detection rate of 10%, and prostate cancer may
be detected in patients with higher level PSA and smaller prostate size.
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UROTHELIAL CARCINOMA OF THE BLADDER: A RETROSPECTIVE
ANALYSIS FROM A SINGLE-CENTER IN TAIWAN
Ming Cheng Luo, Ying-Hsu Chang, Cheng-Keng Chuang, See-Tong Pang,
Po-Hung Lin, Chung-Yi Liu. Divisions of Urology, Department of Surgery,
Chang Gung Memorial Hospital, Linkou, Taiwan
Purpose: Current evidence supports neoadjuvant chemotherapy in the
treatment of advanced bladder cancer. We intend to compare clinical
outcomes in patients treated for MIBC with neoadjuvant chemotherapy at
our institution.
Materials and Methods: We retrospectively reviewed total 26 patients
received neoadjuvant chemotherapy from Jan. 2012 to Feb. 2016 in Linkou
Chang Gung Memorial Hospital. Twenty of 26 patients completed neo-
adjuvant chemotherapy, followed by radical cystectomy and urothelial
bladder carcinoma was pathologically proven.
Results: The median time from diagnosis to operation is 3.45 months
(1.38e3.65). Two of 20 (10%) patients have pathological complete
response, Ten of 20 (50%) patients have partial response and Two of 20
(10%) have stable disease. The mean time of disease free survival (time
from surgery to recurrence) is 22.47 months. The mean time of overall
survival (time from surgery to recurrence) is 25.72 months
Conclusion: Our data revealed that neoadjuvant chemotherapy in bladder
cancer have 10% complete response rate and signiﬁcant downstaging of
urothelial carcinoma with 60%. However, more such studies with larger
sample sizes and longer follow-ups are needed and we intend to stan-
dardize the regimen of neoadjuvant chemotherapy to evaluate the efﬁcacy
much precise.
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Purpose: To explore the involvement of tNOX in capsaicin-exposed
bladder cancer cells, particularly, apoptotic signaling pathways.
Materials and Methods: In this study, we investigated the effect of
capsaicin on human bladder cancer cell lines TSGH 8301, and tried to
clarify the relevant inhibition of cancer of the mechanism. The cell
numbers were detected by ﬂowcytometry. ROS and MMP assay were used
to check cell survival stress and mitochondrial permeability. Western blot
analysis was used to study protein expression proﬁles of apoptosis and cell
cycle arrest.
Results: We found that the TSGH 8301 cell growth was inhibited by
capsaicin with dose dependent and there was signiﬁcant cell apoptosis.
The cell cycle arrested at G1 / S phase. The ROS assay and MMP assay
signiﬁcantly revealed increased cell survival stress and mitochondrial
permeability. By the Western blot analysis, we found that in 100uM and
